NVCR - Earnings call transcript Q2 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to Novocure Second Quarter 2019 Performance Conference Call. [Operator Instructions] As a reminder, this conference call maybe recorded.

I would now like to introduce your host for today’s conference Ms.

Ashley Cordova, Senior Vice President of Finance and Investor Relations. Ma’am you may begin.

Ashley Cordova

thank XXXX joining performance. and Novocure’s to everyone, quarter second morning, you us for review Good Wilco Chief I Chairman, CEO, CFO, Bill joined Doyle; and am today our Asaf by Danziger; Benaim. Officer, Ely Medical our Executive Groenhuysen; our our can second The for on our website, the XXXX our Events section financial results Investor viewed www.novocure.com, slides be on page. clicking by presented on the Relations today quarter link located in

We will would I those during and forward-looking like to forward-looking and that results uncertainties, from you in required time actual except discussions call statements. projected beyond These our of from start, remind this filings. to statements are number our time could conference as uncertainties involve not we publicly update include control, do including these statement, by intend any materially and statements, described which those a law. Before differ risks to of in risks SEC some our

for open release and Following our XX, morning. released press this available our prepared XX-Q, line ended in months and XXXX, remarks for will earlier are June in today, the three six the of questions. we which both we our Financials

turn over the will Bill Doyle. to With I that, now call

Bill Doyle

and everyone. Ashley, good Thank you, morning,

We flow treat mesothelioma combination strong income. our our We pathway. business via operating milestones FDA was device. by development. creation. May, GBM in This which first of chemotherapies and approved drivers System positive In second our are our investments pleural the ever the of approved Cash increased made technology in announce first in to FDA is the fund achieved pleased pipeline we clinical standard HDE business to further and a to value torso long-term commercial with during the NovoTTF-XXXL quarter quarter malignant achieved significant from progress continues on

trials, are most the expansion significant of aggressive treating cancer. forms X four Phase market a We some enrolling creating pivotal opportunity, of

the achieved After third we and important in advancing coverage creation GBM, May Medicare the of determination process, Contractors Administrative milestones of to Medicare Optune diagnosed newly value multi-year certain potential DME proposed compelling a provides the local a beneficiary the quarter. number restrictions. in equipment MACs coverage first for a durable our pipeline, subject into Beyond issued of medical XXXX that continues half of or momentum

XX-day proposed to The the provided LCD five to Comments than period, XX closed and providers MACs groups. more was caregivers, June. by subject in comment a late cancer which public patients advocacy DME and healthcare XXX were

XX not removal the addition, limitations a of FDA policies. the that In private approvals market coverage members CMS to Congress of coverage administrator letter any urging are sent supported by or

public week, to final Optune restrictive major the criteria of originally and response a MACs that September for provides fee for X, final Novocure. comments, revise and This of coverage criteria effective XXXX. proposed. milestone DME the LCD the eliminated or In coverage newly released pricing is GBM, amount diagnosed many schedule Last the

benefit. we’ll to the We Medicare to Optune may expand patients all to process to for to access continue and see a conclusion are pleased work who come coverage

to in during granted, launch and for our be clinical a pursuing regulatory Lab designate clinical China year is Zai Zai an progress application quarter, waiver in the as before Chinese to GBM submitted device Should waiver other Lab medical an In Optune partner the end. trial innovative to trial Optune a indication the has authorities China. intends

the I’ll Asaf. call hand that With introduction, to over

Asaf Danziger

Bill. Thank you,

FDA the was a of generating patients first was asbestos exposure. approved to The record malignant a of May, treatment cancer strongly MPM transformative the first approved rare FDA is mesothelioma that over diagnosed Americans for linked MPM as gross approval metastatic with has In or been million operating income. in treat quarter pleural annually. the net advanced advanced our XX%, second margin quarterly MPM. XX to and achieved with a years $XX.X We quarter locally of represents Novocure. NovoTTF-XXXL unresectable, for by XXXX revenues positive or This

FDA the solid torso tumor approved promise forms indication we Novocure’s approval in The most some multiple shows of TTFields believe and of marks types, the of cancer. also first aggressive including

radiation We MPM launch at by a believe we driving the we phase initiated majority shaped focus learnings for from on adoption GBM XXXX centers will XX that rollout. approximately of the patients. U.S. have MPM our our In and see certifying oncologists

centers will driving we treatment While from MPM exclusive prescriber in teams the critical the at the our know multidisciplinary be oncologist experience to communication adoption. for across the U.S., GBM is cancer radiation that

As are our to that surgeons, field information NovoTTF-XXXL see recommend ensure they oncologist confidently medical to the and pulmonologist teams have patients. patients the such, working needed educate to to MPM

are approval. after IRB multiple with sites the response. and support execution We first MPM by to our been We are less pleased approval. two required weeks FDA early early positive in than has certified ongoing and prescribers information requested the June, initial Certifications

first in We to start the quarter. expect our third therapy MPM patient

to Moving were of net the X,XXX Optune diagnosed period QX revenues an increase XX% represent for with The to quarter’s more end. patients million prescriptions than same GBM number than on of in More newly year. continued versus GBM. patients last at grow. $XX.X

not have of prescribers prescription start flow. our noticeable strength skills communication can influences We will The continue a often to and patient on impact recommendation Optune. or believe a prescriber’s confidence individual of the whether

encourage centers We recommend patients. across have prescribers physician the confidently to teams prepare strengthened speaker to our and at to Optune treatment multidisciplinary GBM programs communication to

sales from has been help launched early also in both to introduce patient intended tool our have acceptance. The We positive. a physicians overwhelmingly physicians patient and manner, friendly Optune to force a feedback increase

clinical to update for now pipeline. the Ely an over on call will our I hand advancing

Ely Benaim

open and allowing therapy pancreatic and you, the Treating cancer XX as Fields. potential preclinical has brain revenue ovarian data solid an X metastases, shown in Asaf, of a indication with lung commencing Phase ongoing have morning shown to four Tumor Fields of cancers. early are in and good as cancer, new X liver Treating across also variety substantial We’ll trials additional cell pivotal everyone. a flow promise cancer, Thank cancer cadence lines Phase tumor solid response Tumor for a indications; by has growth to XXXX. driven tumor that trial a creating

call, METIS. of effectiveness today’s with programs, give will update patients is non-small stereotactic from the radiosurgery cell our Phase each Tumor lung of METIS metastases the Fields with a alone, beginning brief pivotal our testing radiosurgery of on resulting I cancer. Treating stereotactic progress On brain X in plus compare to trial

North in to XXXX. We data anticipate patients ongoing for is and Europe the and sites be have available opened METIS We at trial XX than enrollment across America, Israel. XXX more will

testing with our trials Tumor Treating during docetaxel LUNAR Fields progress docetaxel cell X cancer, the who checkpoint effectiveness platinum-based checkpoint for pivotal patients or immune immune of combination or in after alone lung non-small or Phase versus inhibitors with is inhibitors therapy.

ongoing XX have XXXX the We now sites and America across more half in XXXX. analysis is with from to interim expect than LUNAR final opened enrollment North Europe. in the and at XXX of data patients trial We second the

be PANOVA-X, XXXX data well trials our phase. cancer from recurrent trial and in XXXX INNOVATE-X, our final performing pancreatic cancer will respectively. these ovarian in anticipate ramp-up trial available We and their are

studying in post radiation. trial label initiating working initiating to concurrent of radiation next the the Optune, with expansion, protocol intended potential randomized finalize also Optune are support to benefit GBM, therapy our for We possible versus

provide We updates develop. they on as trials will these

an community, there external the pipeline, is Beyond Treating on Fields increase research driving in Tumor our interest scientific from broadly. clinical

the of Treating preclinical independent XX AACR-Novocure effect spending Grants investigator-sponsored topics have Tumor researchers inovitro which range bench inovitro study April inovitro. trials Research open, XX and are Fields Tumor in the to awarded program a XXXX. a is to of committed expend and enables in inaugural We The ongoing in system studies. Fields We Treating research the

to and Treating partnerships share Fields. expand innovative our similar organizations desire develop to support Tumor research other working We’re that with on

With review finance. to turn I’ll the that, Wilco over call our to

Wilco Groenhuysen

GBM. call Thank us June everyone you, quarter XXXX. morning. ended a thanks joining than of number patients with second as GBM position the the on financial The more to Optune in for an XX, strong have $XXX Novocure this Ely. And than XX X,XXX globally, on treated in of initial XX-month since More has for of patients XX,XXX active quarters patients and presentation data exceed now been revenues grown newly EF-XX consecutive net diagnosed million. trailing the today

that primarily which growing $X in quarter-over-quarter. growth patients we revenues also to driven in of revenues rates, driven rates not do were we year-over-year second Revenue per future an was was by increase significant active improved by improved revenues net million reimbursement patient believe net sustainable. in active reimbursement revenues expect benefit XX% a in XX% are quarters. increase be resulted net net million active The per quarter to additional The quarter Second and approximately and growing an in increase $XX.X patient.

ongoing margin. remain that on this in and efficiency revenues patient million, $XX.X We reflecting Gross per continues in profit scale. quarter sustainable to of focused from a Gross metric. the gross margin the we and key benefit increasing is believe XX% cost reduction active improving was initiatives

increase the to in down the versus we and quarter income a $XX.X investments expenses Moving in with primarily and and statement, million engineering. research trial than Phase R&D XX% increase for with up be quarter clinical second regulatory cost development This medical more continue in an was and XXXX. in of an affairs, driven in our expenses X associated by trials personnel increase pivotal

future patients or that clinical quarters. will continue As anticipate Phase we enrolled R&D expenses worked programs, in we increase four X across to

share. driven of primarily XX% million, million, quarter versus increased Our increased costs. marketing $X.XX by to second was launch expenses $X.X quarter XXXX, or the SG&A second personnel the per for for $XX of expenses of increase loss related quarter Net MPM and were NovoTTF-XXXL the an

GBM short-term $XXX.X Cash We increase and second the clinical quarter. flow quarter and prior the increased the from in $XX investments, cash cash, million business technology investments operations flow funding was our with Cash an from equivalents ended of is million. $X.X in from development. million pipeline

of strive survival some financial Novocure provides cash strengthening with on aggressive extend performance stability our hand as the most we us is to of Our and coupled cancer. forms positive advancing oncology flexibility expansion with with pipeline in platform company flow proprietary therapy, global market opportunity from an multiple significant from growing a an commercial indications. a and cash and established business a in

sustainable on to and both deliver Our existing long-term pipeline. significant disciplined focus is value unwavering from shareholder intended indications our growth near-term from execution

morning. for Thank your time this you

Now I will over questions. turn operator back to call for the the

Operator

our Evercore. from from Thank first you. Instructions] Vijay Kumar question comes And [Operator

Your line open. is

Vijay Kumar

The saying or the not $X maybe Thanks question similar clarify is for you year. a what right? congrats forward. we and guys beat, if This expect was could to this to million this improved going of million on reimbursement. million, saw want understand, incremental on be sustainable. the All sustainable, revenue I increase my $X revenue you’re that $X do just magnitude but is going nice is taking smaller,

Wilco Groenhuysen

Good morning, Vijay, This is Wilco.

on give color million. Let little extra the a bit me try $X to

stated in reimbursement in As we saw the improvements substantial we script, rates.

that from But the applicable is revenue first of XXX. ASC secondly, in improvement. all, have So policy, you which the benefit revenue recognition under

also your then at to And take well. $X as to rates update was within collection able million. that it portfolio. You And estimations that’s have writing particularly, were look a the estimated those we

to driven I we right think, collection be level. quarterly think And that in and compare it’s also going rates in net a comparative not from the it but will a up performance in some anticipates probably an collection revenue So And million sustainable to. level, a – portfolio. it’s million substantial adjustment by at at leading $X our number to $XX uptick was to perspective, continue

Vijay Kumar

see. I

you’re saying, so you $X more one-off it Okay. a million payment. catch-up this what because was – more had a of That’s is

Wilco Groenhuysen

Yes, probably it thanks not That’s describe Yes. to shorted Vijay. efficiently. and way more a

Vijay Kumar

Okay. volumes to And is increase – a quick that up new into I something mesothelioma focus said X%, of implies you from know then no follow-ups so on could correct? script that just GBM up The one, strip it good think, patient patient Street recurring And XQ. from GBM? that first see the sequential performance, couple you me, a versus I was in meso breakdown Is XQ, other

Wilco Groenhuysen

first absolutely all, have not received right that prescription you’re of So a yet. mesothelioma we

in expect QX. We that

entirely And from scripts that’s QX. GBM. saw increase and during the newly X,XXX so this And X% a diagnosed a is quarter, we

Vijay Kumar

XXXX. half Or My last The understanding interim confirm And That’s cell. versus Can the pre-specified the prior And timeline Wilco. on second you expectation the then half Bill, versus in the readout. maybe maybe change could that to was you endpoint if timeline There on the not the curious there readout on did stopped? was would be endpoints on signal, chance no one I’m Is follow-up – Q pass was helpful, of readout. this a are one change. here, it the non-small second have the XQ. is what a just that, trial be here? interim with what

Bill Doyle

Yes.

possibilities any three of interim something our So that clinical there readouts, in course. futility signal. readouts. of think of with One all is I trials never a That’s we’ve is seen

And exceptional trial, circumstances, is be because moving continue can the then target. it’s on trial for Second to the success. stopped in

GBM in trials our was the wouldn’t success. will to interim, X the of our success trial set You’ll for for want that recall I expectation but the be one interim that Phase fact at stopped stopped every at single

Vijay Kumar

That’s helpful guys. you, Thank a though.

Operator

Oppenheimer. Thank you. And from our comes Esther next Rajavelu question from

open. Your line is

Esther Rajavelu

you coverage margin to reimbursement on help pushes on gross for get when a gross can Thank and morning. Good launch pulls expect with – mesothelioma of margin question for I would my Medicare? mesothelioma, Medicare and the from had questions. GBM now the you and launch in us understand for taking you

Wilco Groenhuysen

Esther. morning, bunch of Wilco. questions, whole Good this is It’s a

very disclosure, our Let’s margin start pleased. with gross in stated we as we’re

that scale had revenue you to our commitments with while company of Medicare made dialogue growth entering that the well coverage goods. we that to we’ve as was recall and as one probably to were come We efficiency patients both as a we’ve all Medicare Medicare long into make including available along. inappropriate see we progress of margin, in through But fee. all been and treating continue And the to benefits gross patients, patients, we in to the therapy cost

are So the in P&L. expenses all operating costs, the our

now our revenue we top also So been the we that our benefit expect will but coverage will both published by receive from additional line the margin. fee the has benefit that we’ll gross to and Medicare,

meaningful probably it. I on and depends volume guess bit on little pressure we’ll a in the on MPM, it’s is make that call. early too a progress it any Initially, depends early little comment to really put too but bit reimbursement. on MPM to

Esther Rajavelu

gross overall it offset me sounds to But the the should you. margin hit Got on mesothelioma expect line. reimbursement like we benefit Medicare to that

Wilco Groenhuysen

that’s assumption, yes. I a safe Yes, think

Esther Rajavelu

Okay. Got you.

your the reimbursement the the process – better? Can through. little with there mentioned getting is Okay. you that reimbursement that historically And of then us press claims help years, in you had for go a that the in you several terms over for historical understand last process bit a release can

Bill Doyle

Yes.

CMS. while unfolding. beginning, decision beneficiaries, all So therapy heavily through period we to the backlogged Wilco provide Medicare the from our said, our we were process to that with denials the made strategic Throughout peeled discussions as Medicare with ALJ

the approval our there’s potential appropriate tells that continue no it’s the I We about to expect ALJ time. don’t that to And process. do and for us think to likely settlement this doubt talk recent will appeals through any discussions at

Esther Rajavelu

international Japanese sort that? And you. is of then of front, on in what about from you Got the about they treated nationals? have tourists – all estimates are Or Do medical the China? market, my any on Japan last proportion question Japanese patients are

Asaf Danziger

our patients. that Japanese in the good patient a Japan all It’s It’s question. All Japanese patients, they Asaf. we or treat

Esther Rajavelu

Got you. Thank you very much.

Operator

Thank you.

question from next JPMorgan. Kasimov Cory from Our comes

open. is line Your

Cory Kasimov

guys. for morning good Hey, questions. my Thanks taking

better a going importantly First XQ understand one reimbursement, dynamics for to to bit forward. little is just back trying the going more and

the one-time before even obviously uptake $X excluding kicking had obviously is is nice payment. This in in a that million in. patient quarter you per revenue So Medicare

to talk prior rate So it you then run forward? thinking we about going And little can from XQ? a should bit this be how about quarters

Bill Doyle

month. Yes. Overall, we overall the quarter as about And in X% active that. way. per the reimbursement for instance, $XX,XXX Net patient per U.S., said, improvement seen, good in morning were we by the Corey, rates, revenues in in the improvement year-over-year see we’ve

So predominantly of in United million result rates improved a and the the the $X improvement reimbursements of substantial reimbursement States. is

Cory Kasimov

your X, patients of kicking this us reimbursement just Medicare with within fall you on that then within approved indications September percent the channel? will can in And of Okay. remind

Wilco Groenhuysen

Sure.

are approximately our approval newly of expect patients, The covered is patients coverage for XX% the to those would XX% Medicare those patients. of about we of that policy. said be and of the XX% newly and consistently we’ve majority diagnosed So are diagnosed, under substantial

Cory Kasimov

that those LUNAR being for And of or enrollment is, trials event to XHXX accrual from That’s timelines then by refining to in the coming particular, XXXX that helpful. some driven Okay. regard for question of and interim? initial is last pace of narrowing with going key

Wilco Groenhuysen

of pace the principally accrual. it’s Yes,

into And that little As trials, we getting able patterns why particular that’s we’re further updated to the a specifically. more refine referral number. we’re

Cory Kasimov

Thanks taking the for questions. Okay, great.

Operator

Thank you.

from comes question Greg from next Our Gilbert SunTrust.

is line Your open.

Greg Gilbert

Yes. Hi.

a on as moving then any have the follow-ups. well? number I you follow-up Are LUNAR rapidly enrollment with and a that to is couple PANOVA PD-Xs of question, finding out that. the the On slowing the the timeline are And frontline? drove what issues patients in on And push that

Bill Doyle

Yes.

It area So there have the ongoing. because know, you first result one as trials only timeline other patients The a in big factor. deal. a recruiting combination of though of LUNAR. on some We And don’t particular are main all, particular was has adjustment as any but not effect, not a it’s PANOVA is see difficulty adjusted. any busy may really that been

Greg Gilbert

adjusted talk Okay. Europe? was I Maybe a of think old trends prescriptions? Europe, in info the I then were about trends to demand And Anything active PANOVA versus have patients apologize, relatively prior the it I in should in thought timeline. given there relates quarter be you we as flattish decline can there. aware And quarter. on sequential I

Asaf Danziger

question. It’s you for Asaf. Thank the

believe about any business therapy talk We can of was that benefit see our quarter that our grow mentioned. showed XX%. to patients forward. by just quarter big from these continue many beside in significant year-over-year by will we selling let’s Europe relatively the X%. Last the Germany, prescription day and this events in picture We I So don’t that still thing push

Greg Gilbert

you something don’t then part, And and for for think timeline through? process you mesothelioma. that the lastly, reimbursement can I walk the that this answered Okay. us Is Medicare

Bill Doyle

Sure.

for takes policy September on coverage X the meso, specifically sorry. – effect I’m So,

Greg Gilbert

meso. for Yes,

free, that for get one right? don’t You

Asaf Danziger

will take. So I

patients We will of population. Medicare coverage Medicare we approval will say mentioned, pricing GBM. XX% and meso since So always for the our approach are on approach Medicare we always that we after

we very the our and process GBM. with will work So, to similar Medicare continue with to it’s

So cannot we right define now. any timeline

Greg Gilbert

guys. Thanks, Okay.

Operator

Thank you.

comes Our Difei Yang from from next Mizuho question Securities.

Your open. line is

Difei Yang

Hi. my thanks Good and question. for taking morning,

the us one this of covered? to commercial population a get regards Would walk expecting the mesothelioma through process with side and you the So to timeline quick are coverage. rough you

Bill Doyle

about the GBM I’ve focused time five been last This years. in realized a is sure. question on so I Yes, mesothelioma.

this followed So that GBM also the same process will follow initially.

a at approach then coverage insured, can clinicians So if prescribe then And in to we when level, certain a they’re the become And therapy then on work patients. carriers. volumes will to patient we’ll carriers their basis. privately those policies named establish

take will policy this in So the work on for line. XXXX expect as through material us sort just a standard we through this process. of revenue We everyone don’t

Difei Yang

So takes process. the your three two majority this covered. to it lengthy something years GBM, is with Bill of patients experience like get Maybe from this a is to

Bill Doyle

So, patients applying think is I to it it’s a therapy three function the the of on don’t years. going carriers. take and getting really But then to

compared working, a indications. than is that makes little small areas larger the bit think it of actually I fact some in other relatively a which with indication easier the this to we’re few patients

Difei Yang

if you. GBM decision could this the And comments make to waived. I then, you trial Thank side, be Okay. the whether decision? wonder the with a can XXXX timeline regards China Is from to

Bill Doyle

is expectation So decision. the XXXX a our decision is

Difei Yang

you. Thank Okay.

Operator

you. Thank

question Wedbush Nierengarten next Securities. from Our comes from David

open. is line Your

David Nierengarten

If that prior duration forward I a remind in treatment increase in taking maybe for don’t According any generally would of it of the quarter. differences you to with reimbursement, trend question. the course trial patients age a or math, are for have about going Thanks or world data put on in clinical scientific treatment are that, had know you could us anticipate going but Thanks. to to real Medicare would data It’s duration talk my change my you older, there GBM. bit disclosed meetings. of another if have therapy by on on in way? you in duration

Asaf Danziger

question. Hi. for Thank the you

meaningful are the at our And are experience exact about duration, between no from treatment we So difference treatment but treating not ages. duration difference trials, not we all. expecting in there’s duration different talking

Bill Doyle

this for David, population years. have we remember And been treating patient

David Nierengarten

Yes.

Thank Okay. you.

Operator

a have do we from And follow-up Kumar Instructions] [Operator Vijay Evercore. you. from Thank

Your line is open.

Vijay Kumar

not clarification. one Was this quick commercial – step side? up the million the on $X you side reimbursement Hey mentioned. related The guys, just Medicare that the to or

Wilco Groenhuysen

better improve to It performance, question. be is Thanks, stayed to reimbursement have we performance. don’t we the at Vijay But that going significant for working in said side. result, we hard related second improved is why as we We the And quarter. we and very get to a I that commercial it’s think continued the as saw that’s and are hope of reimbursement. follow-up it a to better

that billing starting question any to then and we do experience payers is September through. different coverage going with And our to commercial go being you and the on and not think fee Medicare Medicare, with effective your on that the X, have be

takes it ramp time up of processes, everything where call out. been Let’s administrative before ironed has certain paperwork process a period it

certain is also So be and QX. difficult very somewhat in we to honest in QX expect to which do that to extent, affect probably to predict,

take flip XX.X. are like and are or going not processes It’s before little a reimbursed switch, it’s being smoothly. working to honed these So the all XX% XX% while at

Vijay Kumar

This Thank is you. helpful.

Operator

you. And have from a follow-up do we Gilbert SunTrust. Greg from Thank

line open. is Your

Greg Gilbert

us how the you but many hope. able think large your it is setting, Thanks. Perhaps population on you color Thanks. frontline up, goes years to trial not access assuming could the give be see in as but do little to would you frontline setting, long a current premature, setting your maybe take the

Bill Doyle

Sure.

I another think it require trial. Greg, So clinical it would – will

years detail frontline. really move four an planned to yet. or we more haven’t So it’s to three area is probably in This that to out

So with of typical our say, any I’d indications. one

Greg Gilbert

Thanks. Okay.

Operator

any for remarks. showing no phone from further I I’d Thank turn closing our the you. like lines. to Bill now questions back And to conference over am Doyle

Bill Doyle

Sure.

So you I your and in thank for line the everybody thank continued interest to want on first of all, Novocure.

a and quarter remarks, during As received really Medicare for Asaf We coverage was Novocure. QX transformative his reimbursement. said

FDA something ever had resulted our approval which income. increased quarter margin as that this is with positive first for strong years. torso been revenue our think We operating and We’ve growth mesothelioma, first know, in working I you gross we’ve received indication. on our for

that continued development. funding and positive program, particularly R&D is important the is backdrop progress Phase X We generating in the I clinical still our is which this here made think clearly given in continued we’re driver income. growth for of contributions couldn’t team. long-term And our feel more value And contributions couldn’t positioned as our our particularly of all the We for be our clinicians thankful in expansion. patients. drive well core more thankful strategies. for we And this we our is operating our be the today our of technology we forward and

you all. thank So

Operator

and does Ladies thank the in you participating gentlemen, for conclude conference. program. today’s This

disconnect. You may all have day. a Everyone wonderful

NovoCure Limited (NVCR) 25 Jul 192019 Q2 Earnings call transcript